Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Jul 2023)

Consensus recommendations for clinical assessment tools for the diagnosis of posterior cortical atrophy syndrome from the Atypical AD PIA of ISTAART

  • Victoria S. Pelak,
  • David F. Tang‐Wai,
  • Bradley F. Boeve,
  • Femke H. Bouwman,
  • Jonathan Graff‐Radford,
  • Gil Rabinovici,
  • Samantha K. Holden,
  • Ryan A. Townley,
  • Gregory S. Day,
  • Jennifer Whitwell,
  • Rik Ossenkoppele,
  • Baayla D. C. Boon,
  • Deepti Putcha,
  • Chiadi U. Onyike,
  • Heather Snyder,
  • Sebastian Crutch,
  • Keir X. X. Yong

DOI
https://doi.org/10.1002/dad2.12474
Journal volume & issue
Vol. 15, no. 3
pp. n/a – n/a

Abstract

Read online

Abstract INTRODUCTION Delay in diagnosis of posterior cortical atrophy (PCA) syndrome is common, and the lack of familiarity with assessment tools for identifying visual cortical dysfunction is a contributing factor. We propose recommendations for the approach to the evaluation of PCA clinical features during the office visit, the neuropsychological evaluation, and the research setting. A recommended screening battery for eye clinics is also proposed. METHODS Recommendations were developed using results from a web‐based survey of members of Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) Atypical Alzheimer's Disease Professional Interest Area (PIA), literature review, and consensus by the PCA assessment working party of the Atypical Alzheimer's Disease PIA. RESULTS Survey results revealed robust agreement for assessment tool preferences for PCA features, and many respondents indicated that they reserve assessment tools for use only when PCA is suspected. For some PCA features, curated tools were preferred over validated battery tools, particularly for the office visit. Consensus recommendations superseded survey preferences for two core cognitive features within the 2017 PCA diagnostic criteria. DISCUSSION These consensus recommendations provide an evaluation framework for PCA clinical features and can facilitate timely and accurate recognition and diagnosis of PCA. Broader use of these tools should be sought, and development and validation of novel PCA clinical outcome assessments are needed to improve our understanding of atypical AD and other dementias and support the inclusion of those with PCA in treatment trials.

Keywords